https://orcid.org/0000-0002-7708-4391
Figures & data
Figure 1 H&E staining of triple primary tumors and metastatic bone tumors of the case. (A and B) Primary lung SQCC (40x, 100x); (C and D) Immunohistochemistry staining of p63 and TTF1 for SQCC; (E and F) Primary CCRCC (40x, 100x); (G and H) Metastatic bone tumor (40x, 100x); (I and J) Primary prostate adenocarcinoma.
Figure 2 CT images reflect the dynamic changes of the patient’s responses to the treatment plans. (A) Size of lung SQCC (1.7x1.7 cm, red dotted line) soon after the initial diagnosis by fiberoptic bronchoscopy; (B) Radiation pneumonitis and unchanged tumor size (1.7x1.7 cm, red dotted line) after radiotherapy; C) Radiation pneumonitis and increased tumor size (2.1x2.8 cm, red dotted line) after radiotherapy; (D) Increased tumor size (3.1x9.4 cm, red dotted line) after platinum-based chemotherapy; (E) Reduced tumor size (3.5x6.3 cm, red dotted line) 4 months after targeted therapy; (F) Further reduced tumor size (2.47x2.47 cm, red dotted line) 9 months after targeted therapy; (G and H) Follow-up images of CCRC and prostate adenocarcinoma in 2015 showed no sign of tumor recurrence.
Table 1 Mutation Profiles of the Lung Squamous Cell Carcinoma, Renal Clear Cell Carcinoma, Prostate Adenocarcinoma and Metastatic Bone Tumor Using Targeted Exome Sequencing